{"entity":{"id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","aka":["ARTEMIA"],"tldr":"A phase 3 trial testing OSE2101 in non-small-cell lung cancer, now recruiting.","summary":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor is a phase 3 interventional study registered as NCT06472245, led by OSE Immunotherapeutics with Exystat and GeneDx, and recruiting on the registry. Official title: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor. Planned enrolment is 363 participants (estimated). The study started in 2024-12-03 and primary completion is expected in 2027-12-15. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06472245","url":"https://clinicaltrials.gov/study/NCT06472245"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ose2101"],"companies":["ose-immunotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06472245","phase":"3","setting":"A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor","sponsor":"OSE Immunotherapeutics","started":"2024-12-03","startedType":"actual","enrolled":363,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06472245/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/"}],"company":[{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/"}]}}